• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].

作者信息

Qin S C, Jiang R, Sha Y Q, Qiu J Y, Mi H L, Miao Y, Wu W, Wang L, Fan L, Xu W, Li J Y, Zhu H Y

机构信息

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.

Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):158-161. doi: 10.3760/cma.j.issn.0253-2727.2023.02.014.

DOI:10.3760/cma.j.issn.0253-2727.2023.02.014
PMID:36948873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10033273/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc6d/10033273/2dac098af3ae/cjh-44-02-158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc6d/10033273/2dac098af3ae/cjh-44-02-158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc6d/10033273/2dac098af3ae/cjh-44-02-158-g001.jpg

相似文献

1
[Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].布鲁顿酪氨酸激酶（BTK）抑制剂联合苯达莫司汀和利妥昔单抗一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):158-161. doi: 10.3760/cma.j.issn.0253-2727.2023.02.014.
2
Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients.布鲁顿酪氨酸激酶抑制剂与苯达莫司汀和利妥昔单抗治疗慢性淋巴细胞白血病患者的成本效益
Future Oncol. 2023 Dec;19(38):2525-2536. doi: 10.2217/fon-2023-0574. Epub 2023 Dec 7.
3
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.伊布替尼联合苯达莫司汀和利妥昔单抗对比安慰剂、苯达莫司汀和利妥昔单抗治疗既往治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（HELIOS）：一项随机、双盲、III 期研究。
Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5.
4
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.苯达莫司汀和利妥昔单抗在未经治疗的先前不适合的慢性淋巴细胞白血病患者中的疗效。在真实环境中与伊布替尼的间接比较。一项 GIMEMA-ERIC 和美国的研究。
Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
5
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.选择性 BTK 抑制可提高苯达莫司汀治疗反应并使慢性淋巴细胞白血病中的免疫效应功能正常化。
Int J Cancer. 2019 Jun 1;144(11):2762-2773. doi: 10.1002/ijc.32010. Epub 2019 Jan 16.
6
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.苯达莫司汀在慢性淋巴细胞白血病患者中的常规应用：一项观察性研究。
Anticancer Res. 2015 Sep;35(9):5129-39.
7
Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia.泽布替尼与苯达莫司汀和利妥昔单抗治疗初治慢性淋巴细胞白血病的成本效果比较。
Clin Ther. 2024 Nov;46(11):877-882. doi: 10.1016/j.clinthera.2024.08.016. Epub 2024 Sep 16.
8
Combo Therapy Effective for Relapsed CLL.联合疗法对复发慢性淋巴细胞白血病有效。
Cancer Discov. 2015 Jul;5(7):OF8. doi: 10.1158/2159-8290.CD-NB2015-081. Epub 2015 Jun 1.
9
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.联盟 A041202/CCTG CLC.2 前瞻性经济分析：随机 III 期试验结果，比较苯达莫司汀-利妥昔单抗与伊布替尼方案治疗未经治疗的老年慢性淋巴细胞白血病患者。
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):766-774. doi: 10.1016/j.clml.2021.06.011. Epub 2021 Jul 3.
10
Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.苯达莫司汀和利妥昔单抗治疗慢性淋巴细胞白血病后早期直接抗球蛋白试验阴性：两例报告
Turk J Haematol. 2018 Nov 13;35(4):312-313. doi: 10.4274/tjh.2017.0464. Epub 2018 Jul 9.

本文引用的文献

1
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.RESONATE-2 研究的 8 年随访结果：伊布替尼一线治疗慢性淋巴细胞白血病患者。
Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434.
2
Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday.限时联合治疗方案在慢性淋巴细胞白血病中的应用：实现药物假期的有前途策略。
Curr Med Sci. 2021 Jun;41(3):431-442. doi: 10.1007/s11596-021-2385-3. Epub 2021 Jun 28.
3
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
针对 B 细胞恶性肿瘤中的布鲁顿酪氨酸激酶使用非共价抑制剂。
J Hematol Oncol. 2021 Mar 6;14(1):40. doi: 10.1186/s13045-021-01049-7.
4
Chemotherapy-free frontline therapy for CLL: is it worth it?CLL 一线治疗无化疗：值得吗？
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):24-32. doi: 10.1182/hematology.2020000085.
5
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.CLL 中采用固定时间、可衡量的残留病灶指导治疗方法：来自 2 期 ICLL-07 FILO 试验的随访数据。
Blood. 2021 Feb 25;137(8):1019-1023. doi: 10.1182/blood.2020008164.
6
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.维奈托克和伊布替尼用于复发/难治性慢性淋巴细胞白血病患者。
Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.
7
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.伊布替尼治疗的慢性淋巴细胞白血病患者预后的预测：建立并验证一个四因素预后模型。
J Clin Oncol. 2021 Feb 20;39(6):576-585. doi: 10.1200/JCO.20.00979. Epub 2020 Oct 7.
8
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.维奈托克联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（CLL14）：一项多中心、开放标签、随机、3 期临床试验的随访结果。
Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.
9
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.泽布替尼治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的疗效：一项 2 期、单臂、多中心研究。
J Hematol Oncol. 2020 May 11;13(1):48. doi: 10.1186/s13045-020-00884-4.
10
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.